Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc.’s Global General Counsel and Secretary, Michael J. Rider, has reported the sale of 50 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, leaving him with beneficial ownership of 9,741 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 28 February 2025, indicating the sale was made according to a preset schedule and may help mitigate concerns about discretionary insider trading among investors and other stakeholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a global medical technology company specializing in cloud-connected devices and software solutions for the diagnosis, treatment and management of sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company focuses on home-based and non-invasive therapies that support patients, hospitals and sleep clinics, with its shares traded on major exchanges, including via CHESS Depositary Interests in Australia.
Average Trading Volume: 1,171,191
Technical Sentiment Signal: Buy
Current Market Cap: A$53.07B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.